Leen Kawas is a prominent leader in the biotech industry and serves as the CEO of M3 Biotechnology, a company dedicated to finding treatments for neurodegenerative diseases.
Prior to her current position, Leen Kawas earned her PhD in molecular pharmacology and cancer therapeutics from the State University of New York. She then went on to work in the biotech industry, holding various positions at leading companies such as Amgen, Novartis, and Genzyme.
Leen Kawas has received numerous accolades for her work, including being named one of the Puget Sound Business Journal’s “40 Under 40” and one of the “Top Women in Biotech” by the Boston Business Journal.
Under Leen Kawas’ leadership, M3 Biotechnology has made significant strides in the development of therapeutics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s mission is to target the underlying mechanisms of these diseases and develop treatments that can slow or reverse their progression.
Leen is also committed to promoting diversity and inclusion in the biotech industry. She serves on the board of the Healthcare Businesswomen’s Association and has been recognized for her efforts to support women in science and technology.
Leen Kawas is a prominent figure in the biotech industry, serving as the CEO of M3 Biotechnology, a company dedicated to finding innovative treatments for neurodegenerative diseases. Dr. Kawas holds a PhD in molecular pharmacology and cancer therapeutics from the State University of New York and has extensive experience in the biotech industry.
Throughout her career, Leen has held executive positions at major biotech companies such as Amgen, Novartis, and Genzyme. She has been recognized for her contributions to the industry, receiving honors such as being named one of the “Top Women in Biotech” by the Boston Business Journal and being listed as one of the Puget Sound Business Journal’s.